Skip to main content
Archived articles

Alzheimer's disease

Research in action
Alzheimer's blood test could be a 'game-changer'
Published Aug 5, 2025 Video
The test, developed in part by Johns Hopkins researchers, will dramatically increase access to early detection and treatment
Research in action
A group effort to understand Alzheimer's disease
Published Aug 5, 2025
A longitudinal study at Johns Hopkins that began in 1995 depends on the dedication of hundreds of people as well as NIH support
Neuroscience
How misfolded proteins may contribute to Alzheimer's, dementia
Published July 11, 2025
New study suggests more than 200 types of misfolded proteins could be associated with age-related cognitive decline
Biochemistry
A master of protein origami
Published Summer 2025 Video
Johns Hopkins chemist Stephen Fried has spent decades investigating how protein cells fold, unfold, and misfold, a cause of many neurodegenerative diseases and our cognitive decline. His pioneering work could provide the basis for humans living longer, better, and with our memories intact. / Johns Hopkins Magazine
Research matters
Earlier, better treatments for Alzheimer's disease
Published March 17, 2025
Federally funded research at Johns Hopkins offers new avenues for detecting brain disease long before it strikes
Innovative care
Hopkins AITC announces additional awardees of second funding round
Published Jan 5, 2024
Grant recipients will receive funding to develop new artificial intelligence technologies to promote healthy aging
Innovative care
Hopkins AITC announces awardees of second funding round
Published June 16, 2023
Grant recipients–hailing from academia, industry, and clinical practice—will receive funding to develop new devices and other aging-related innovations
Innovative care
Aging well with AI: Hopkins AITC announces awardees of pilot research grants
Published Jan 10, 2023
Inaugural grant recipients hailing from academia, industry, and clinical practice will receive funding to develop new devices and other aging-related innovations
Hope for Alzheimer's
Published Fall 2021
Two Johns Hopkins researchers race to bring a drug to market that holds promise for millions afflicted with the devastating cognitive disorder / Johns Hopkins Magazine
Q+A
Insights on FDA's controversial approval of Alzheimer's drug
Published June 21, 2021
Supriya Munshaw, an expert in drug commercialization, discusses what factors went into the FDA approval of aducanumab, a drug known by the brand name Aduhelm